Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:TYP) ) has provided an announcement.
Tryptamine Therapeutics has strengthened its clinical development team with the appointments of Professor Marcel Mozafari as Senior Formulation Scientist and Professor David Castle as Consultant Medical Officer. These appointments come as Tryp prepares for a world-first clinical trial of their lead drug candidate, TRP-8803, for treating Binge Eating Disorder in collaboration with Swinburne University. The new team members bring significant expertise and are expected to enhance the company’s operational capabilities and strategic oversight, positioning Tryp for potential growth in the psychedelic therapy market.
More about Tryptamine Therapeutics
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Their lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin, aimed at improving the treatment of conditions like binge eating disorder, fibromyalgia, and irritable bowel syndrome.
Average Trading Volume: 1,539,327
Technical Sentiment Signal: Sell
Current Market Cap: A$44.61M
Learn more about TYP stock on TipRanks’ Stock Analysis page.